Table 3. . The frequency of mutant genes in the MDS and MDS/AML groups.
| Gene mutation | MDS (n = 71) | MDS/AML (n = 28) | p-value |
|---|---|---|---|
| U2AF1 | 30.99% (22/71) | 25% (7/28) | 0.630 |
| ASXL1 | 22.54% (16/71) | 21.43% (6/28) | 1 |
| RUNX1 | 16.9% (12/71) | 10.71% (3/28) | 0.546 |
| TP53 | 12.68% (9/71) | 21.43% (6/28) | 0.351 |
| NRAS | 12.68% (9/71) | 17.86% (5/28) | 0.530 |
| SETBP1 | 12.68% (9/71) | 14.29% (4/28) | 1 |
| ETV6 | 9.86% (7/71) | 7.14% (2/28) | 1 |
| GATA2 | 7.04% (5/71) | 14.29% (4/28) | 0.266 |
| TET2 | 8.45% (6/71) | 10.71% (3/28) | 0.710 |
| NPM1 | 4.23% (3/71) | 14.29% (4/28) | 0.097 |
| PTPN11 | 2.82% (2/71) | 17.86% (5/28) | 0.018 |
| SF3B1 | 8.45% (6/71) | 3.57% (1/28) | 0.669 |
| CEBPA | 4.23% (3/71) | 10.71% (3/28) | 0.347 |
| IDH1 | 4.23% (3/71) | 10.71% (3/28) | 0.347 |
| IDH2 | 4.23% (3/71) | 7.14% (2/28) | 0.620 |
| WT1 | 4.23% (3/71) | 7.14% (2/28) | 0.620 |
| CBL | 4.23% (3/71) | 3.57% (1/28) | 1 |
| EZH2 | 4.23% (3/71) | 3.57% (1/28) | 1 |
| FLT3 | 0 | 14.29% (4/28) | 0.005 |
| KRAS | 1.41% (1/71) | 10.71% (3/28) | 0.067 |
| PHF6 | 5.63% (4/71) | 0 | 0.575 |
Genes mutated in fewer than four patients are not listed.
AML: Acute myeloid leukemia; MDS: Myelodysplastic syndrome.